Klaricid (Clarithromycin)

Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking the translocation step of peptide chain elongation. This action halts bacterial growth, producing a bacteriostatic effect against susceptible Gram‑positive and certain Gram‑negative organisms.

The dosage of Klaricid is individualized by the prescribing clinician according to the infection being treated, patient age, weight, renal and hepatic function, and other clinical factors. Patients should follow the exact regimen provided by their healthcare provider.

Safety data for clarithromycin in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any potential risk to the fetus or infant. Pregnant or nursing individuals must discuss use with their healthcare professional.

To order Klaricid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Clarithromycin offers a broader spectrum against certain atypical pathogens compared with azithromycin and has a longer half‑life, allowing twice‑daily dosing. However, it has a higher potential for drug‑drug interactions via CYP3A4 inhibition. Choice of macrolide depends on the infection, patient tolerance, and interaction profile.

Klaricid should be stored at ambient temperature, below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and do not use after the expiry date indicated on the packaging.

Klaricid is taken orally, usually with a full glass of water. It may be taken with or without food, although taking it with food can reduce gastrointestinal upset. The exact administration schedule is determined by the prescribing clinician.

Serious risks include hepatic dysfunction, QT‑interval prolongation leading to potentially life‑threatening arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and rare cases of irreversible hearing loss. Patients should seek immediate medical attention if they experience symptoms like chest pain, palpitations, severe rash, or persistent diarrhea.

Klaricid is contraindicated in individuals with a known hypersensitivity to clarithromycin, other macrolides, or any component of the formulation. It should also be avoided in patients with a history of significant QT prolongation or ventricular arrhythmias unless the benefits outweigh the risks and appropriate monitoring is in place.